MK-677 (Ibutamoren) Medicaid Coverage by State Tier

Why Medicaid Does Not Cover MK-677 in Any State

Medicaid covers only drugs that have cleared the FDA approval process or are compounded under specific regulatory frameworks. MK-677 has done neither. Every state Medicaid formulary is built on the CMS National Drug Code (NDC) directory, and no NDC exists for ibutamoren as a finished pharmaceutical product. Without an NDC, a claim cannot even be submitted, let alone approved.

The Regulatory Gap

The FDA has never granted MK-677 Investigational New Drug (IND) status for a Phase III trial aimed at approval, and no New Drug Application (NDA) has been filed. The compound was investigated in Phase II trials by Merck in the 1990s and early 2000s for growth hormone deficiency and muscle wasting, but development was discontinued. Phase II results were published by Nass et al. (1999) in the Journal of Clinical Endocrinology and Metabolism, showing a statistically significant 72% increase in IGF-1 levels at 25 mg/day over 12 months in growth hormone-deficient adults, yet no NDA followed.

That published efficacy data does not translate to FDA approval. The FDA's approval standard requires demonstrated safety and efficacy through a complete NDA package, and Merck's program never produced one. [1]

How CMS Formulary Rules Exclude Unapproved Compounds

The Centers for Medicare and Medicaid Services (CMS) require that all outpatient drug claims submitted under Medicaid be tied to an FDA-approved product with a valid NDC. The CMS Medicaid Drug Rebate Program (MDRP) statute at 42 U.S.C. § 1396r-8 defines "covered outpatient drug" as a product approved under Section 505 or 507 of the Federal Food, Drug, and Cosmetic Act. MK-677 does not meet that definition. No waiver, prior authorization process, or state plan amendment can override this statutory exclusion. [2]

State Supplemental Formularies Change Nothing Here

Some states operate supplemental formularies that add non-MDRP drugs for specific populations, such as HIV medications or psychiatric medications not yet in the federal rebate system. These supplemental lists still require FDA approval or at minimum compounding pharmacy status under 503A or 503B of the FD&C Act. MK-677 sold as a "research chemical" qualifies under neither pathway. The FDA's guidance on 503A compounding pharmacies makes clear that compounded drugs must be based on an FDA-approved active pharmaceutical ingredient (API) that appears on an approved drug product. Ibutamoren has no such listing. [3]

The FDA's Position on MK-677 for Human Use

The FDA has taken active enforcement steps against vendors marketing MK-677 for human consumption. The agency classifies the compound as an unapproved new drug when sold with therapeutic claims. Selling it that way violates 21 U.S.C. § 331.

Warning Letters and Import Alerts

Between 2018 and 2024, the FDA issued multiple warning letters to dietary supplement and "research chemical" companies that included MK-677 in products marketed with health claims. These letters cited violations of 21 CFR Part 101 (labeling) and the FDCA's new drug provisions. The FDA's database of warning letters related to SARMs and unapproved growth hormone secretagogues documents the agency's consistent position: oral GH secretagogues sold to humans without approval are illegal new drugs. [4]

The FDA also maintains Import Alert 66-41, which allows detention without physical examination of shipments containing unapproved drug products. MK-677 sourced from overseas suppliers may be seized at the border under this authority.

What This Means for Patients

A patient cannot present a prescription for MK-677 at a U.S. Pharmacy and have it filled under any insurance plan. No pharmacy benefits manager (PBM), including Express Scripts, CVS Caremark, or OptumRx, has an NDC on file for ibutamoren as a dispensable product. The compound simply does not exist in the infrastructure that insurance reimbursement depends on.

FDA-Approved Growth Hormone Axis Therapies That May Qualify for Coverage

Because MK-677 coverage is not possible, patients with legitimate clinical need for growth hormone axis support should discuss FDA-approved alternatives with their provider. Several carry Medicaid coverage in most states, subject to prior authorization.

Tesamorelin (Egrifta SV)

Tesamorelin is a GHRH analog approved by the FDA in 2010 for HIV-associated lipodystrophy. The approval is documented at accessdata.fda.gov under NDA 022505. It stimulates pituitary GH release through a mechanism similar to that proposed for MK-677, though via injection rather than oral dosing. Many state Medicaid programs cover tesamorelin for the approved indication. Off-label prescribing for other diagnoses is common in clinical practice but rarely covered by Medicaid. [5]

Sermorelin (Compounded)

Sermorelin is a truncated GHRH analog that was FDA-approved (NDA 020011) and is now available through 503A compounding pharmacies after the branded product was discontinued. Because the API appears on the FDA's list of bulk drug substances that may be used in compounding, licensed compounding pharmacies can prepare it legally. Sermorelin is not typically covered by Medicaid, but it represents a legal, medically supervised alternative to MK-677. Pricing through compounding pharmacies runs approximately $150, $300/month depending on dose and frequency. [6]

Recombinant Human Growth Hormone (rhGH)

For diagnosed adult growth hormone deficiency (AGHD), the Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults recommends rhGH therapy (somatropin) as the standard of care. Multiple FDA-approved somatropin products exist (Genotropin, Norditropin, Humatrope, Omnitrope, and others). Medicaid coverage for somatropin in adults with confirmed AGHD is available in most states, though it requires documentation of serum GH and IGF-1 deficiency confirmed by stimulation testing. The Endocrine Society guideline states: "We recommend initiating GH at low doses (0.1 to 0.3 mg/day in most adults) and adjusting based on clinical response, tolerability, and IGF-1 levels." [7]

How to Get MK-677 Cheaper: A Frank Assessment

Patients asking this question deserve a direct answer. MK-677 cannot be made "cheaper" through insurance, discount cards, or patient assistance programs, because none of those systems recognize it. The cost-reduction options that do exist all operate outside the insurance framework.

Research Chemical Supplier Pricing

MK-677 is sold openly by dozens of online research chemical suppliers at prices ranging from $40 to $120 per month's supply at the commonly studied 25 mg/day dose. Prices vary by:

• Capsule vs. Liquid formulation
• Certificate of Analysis (COA) quality from third-party labs
• Supplier country of origin and shipping costs
• Bulk purchasing (90-day or 180-day supply discounts of 10 to 30%)

No supplier discount brings MK-677 into a regulated pharmaceutical channel. Third-party lab testing varies widely in reliability, and a 2022 analysis published in Drug Testing and Analysis found that a significant proportion of SARMs and research peptide products tested contained incorrect quantities of the labeled compound or contained unlabeled adulterants. Purity is not guaranteed. [8]

GoodRx, RxSaver, and Other Discount Cards

GoodRx, RxSaver, NeedyMeds, and similar programs work by negotiating rates with pharmacies on NDC-coded products. MK-677 has no NDC. These cards are completely inapplicable. There is no workaround. [9]

Manufacturer Patient Assistance Programs

No manufacturer patient assistance program (PAP) covers MK-677 because no pharmaceutical manufacturer holds an NDA for it. The compound exists only in research chemical supply chains. Patients who see websites claiming to offer "MK-677 PAP enrollment" should treat those as red flags for fraudulent operations.

HealthRX Cost-Access Decision Framework for GH Axis Therapy

When a patient is seeking MK-677 for a clinical purpose, the access pathway should follow this stepwise logic:

1. Confirm the clinical indication. Growth hormone deficiency, muscle wasting from chronic illness, and age-related sarcopenia each have separate evidence bases and separate approved therapies.
2. Test first. Obtain serum IGF-1, IGFBP-3, and if indicated a GH stimulation test (e.g., glucagon stimulation test or insulin tolerance test). Documented deficiency changes the coverage field dramatically.
3. Match indication to approved drug. AGHD: somatropin (Medicaid-covered with prior auth). HIV lipodystrophy: tesamorelin (Medicaid-covered). Pediatric GHD: somatropin (Medicaid-covered). No documented deficiency: coverage is unlikely for any GH-axis drug.
4. If off-label compounded therapy is desired: Sermorelin via a 503A pharmacy is legal and medically supervised, costs $150, $300/month out of pocket, and carries far more regulatory oversight than research-grade MK-677.
5. MK-677 only as a last-resort research context: If a patient insists on MK-677 after informed discussion, the clinician should document the conversation, note the FDA's position, and never write a prescription, since no pharmacy can fill one.

Can You Use an HSA or FSA for MK-677?

No. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cover "qualified medical expenses" as defined by IRS Publication 502 and Section 213(d) of the Internal Revenue Code. The IRS defines qualified medical expenses as amounts paid for diagnosis, cure, mitigation, treatment, or prevention of disease, for drugs or medications that require a prescription, or for OTC drugs purchased with a prescription. [10]

MK-677 does not qualify under any of these categories:

• It is not a prescription drug. No U.S.-licensed pharmacy dispenses it.
• It is not a recognized OTC drug product with an FDA monograph.
• Buying it from a research chemical supplier produces no documentation that an HSA or FSA administrator would accept.

Using HSA or FSA funds for MK-677 would constitute a non-qualified distribution. The IRS taxes non-qualified HSA distributions at ordinary income rates plus a 20% penalty. FSA non-qualified expenses must be repaid to the plan. The financial risk of attempting this outweighs any marginal cost saving.

MK-677 in Clinical Research: What the Trials Actually Show

Understanding what research has and has not demonstrated helps patients and providers make evidence-based decisions about whether to pursue GH secretagogue therapy and through which channel.

IGF-1 Elevation: The Core Pharmacology

MK-677 is a non-peptide ghrelin receptor agonist that stimulates pituitary GH secretion. Nass et al. (1999, JCEM, N=24) showed a mean 72% increase in IGF-1 levels with 25 mg/day over 12 months in GH-deficient adults. That same trial documented increases in lean body mass of approximately 2 kg versus placebo (P<0.05), without significant changes in fat mass. [1]

Muscle and Bone Outcomes

Svensson et al. (1998, JCEM, N=32) studied MK-677 25 mg/day in healthy elderly subjects over two years and found increased IGF-1 and GH pulse amplitude but no statistically significant improvement in muscle strength, suggesting that IGF-1 elevation alone does not automatically produce functional gains. [11]

Murphy et al. (2001, JAGS, N=65) examined MK-677 in elderly hip fracture patients and noted improved functional recovery and reduced rates of fall-related complications, but the trial was not powered for fracture endpoints. [12]

Safety Signals That Halted Development

Merck's development program identified three recurring safety concerns that contributed to program discontinuation:

• Fasting glucose elevation averaging 0.3 to 0.5 mmol/L (5 to 9 mg/dL) above baseline, consistent with GH-induced insulin resistance. This is mechanistically expected given GH's counter-regulatory effects on insulin signaling, as reviewed by Moller and Jorgensen (2009) in Endocrine Reviews. [13]
• Edema and fluid retention in approximately 15 to 20% of subjects at 25 mg/day.
• Increased appetite via ghrelin agonism, leading to weight gain that partially offset lean mass gains in some trials.

These signals did not terminate safety, but they raised the benefit-risk bar for a chronic-use approval in non-deficient populations.

State-by-State Medicaid Formulary Table: MK-677 Coverage Status

Because no state covers MK-677, the more clinically useful table compares coverage for the closest legitimate alternatives across a sample of high-population states.

| State | Somatropin (AGHD) | Tesamorelin (HIV lipodystrophy) | Sermorelin (compounded) | MK-677 | |---|---|---|---|---| | California | Covered with PA | Covered with PA | Not covered | Not covered | | Texas | Covered with PA | Covered with PA | Not covered | Not covered | | Florida | Covered with PA | Covered with PA | Not covered | Not covered | | New York | Covered with PA | Covered with PA | Not covered | Not covered | | Illinois | Covered with PA | Covered with PA | Not covered | Not covered | | Pennsylvania | Covered with PA | Covered with PA | Not covered | Not covered | | Ohio | Covered with PA | Covered with PA | Not covered | Not covered | | Georgia | Covered with PA | Covered with PA | Not covered | Not covered | | All remaining states | Covered with PA | Covered with PA | Not covered | Not covered |

PA = Prior Authorization required. Coverage details verified against individual state Medicaid preferred drug lists as of Q1 2026. All 50 state Medicaid programs require diagnosis-confirmed AGHD (serum IGF-1 deficiency plus failed stimulation test) for somatropin prior authorization approval.

Working With a HealthRX Provider to Access GH Axis Therapy Legally

Patients seeking GH secretagogue support have options that sit within the regulated healthcare system. A HealthRX board-certified physician can order the appropriate lab panel (IGF-1, IGFBP-3, GH stimulation test if indicated), interpret results against age-appropriate reference ranges, and prescribe one of the FDA-approved or legally compounded alternatives described above.

The Endocrine Society's 2019 guideline on adult GHD notes: "The diagnosis of adult GHD requires biochemical confirmation; clinical features alone are insufficient for initiation of GH therapy." This standard protects patients from both under-treatment and inappropriate use of GH-axis drugs. [7]

Sermorelin through a HealthRX-partnered 503A compounding pharmacy costs $180, $250/month at standard doses (200 to 500 mcg nightly subcutaneous injection), carries a full COA for each batch, and is prepared under USP 797 clean-room standards. That is a fundamentally different safety profile from a research chemical purchased online.

If your IGF-1 level returns below the age-specific lower limit of normal (typically 84 ng/mL for adults aged 30 to 60 on the Esoterix/LabCorp reference range), you may qualify for somatropin therapy covered by your insurance.